Deprescribing or represcribing: not just a semantic dilemma
- PMID: 34738225
- PMCID: PMC9151539
- DOI: 10.1007/s41999-021-00583-4
Deprescribing or represcribing: not just a semantic dilemma
Conflict of interest statement
MW was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Heel, Bristol-Myers, Daichii-Sankyo, Santhera, Lilly, Otsuka, Novo-Nordisk, Shire and LEO Pharma. MP has no conflicts of interest to declare.
References
-
- American Geriatrics Society Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;2019(67):674–694. - PubMed
-
- Zhang H, Wong ELY, Wong SYS, Chau PYK, Yip BHK, Chung RYN, Lee EKP, Lai FTT, Yeoh EK. Comparison of adaptive versions of the Hong Kong-specific criteria and 2015 Beers criteria for assessing potentially inappropriate medication use in Hong Kong older patients. BMC Geriatr. 2021;21(1):379. doi: 10.1186/s12877-021-02324-5. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources